Woodline Partners LP Has $12.67 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Woodline Partners LP increased its stake in Jazz Pharmaceuticals by 31.6%, acquiring an additional 24,486 shares, bringing its total ownership to 102,050 shares worth approximately $12.67 million.
• Analysts have shown optimism for Jazz Pharmaceuticals, with ratings upgraded by several brokerages, including Zacks, Truist Financial, and Royal Bank Of Canada, giving buy ratings and price targets ranging from $151 to $205.
• Jazz Pharmaceuticals reported a substantial earnings miss with an EPS of ($8.25), significantly below estimates, despite revenue reaching $1.05 billion for the quarter.

Woodline Partners LP raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 31.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 102,050 shares of the specialty pharmaceutical company's stock after buying an additional 24,486 shares during the quarter. Woodline Partners LP owned 0.17% of Jazz Pharmaceuticals worth $12,670,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. Captrust Financial Advisors increased its holdings in Jazz Pharmaceuticals by 7.5% in the 4th quarter. Captrust Financial Advisors now owns 5,337 shares of the specialty pharmaceutical company's stock valued at $657,000 after buying an additional 372 shares during the period. Cetera Investment Advisers acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $1,243,000. EP Wealth Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $217,000. Deutsche Bank AG boosted its stake in shares of Jazz Pharmaceuticals by 4.0% in the 4th quarter. Deutsche Bank AG now owns 16,012 shares of the specialty pharmaceutical company's stock valued at $1,972,000 after purchasing an additional 609 shares in the last quarter. Finally, Focus Partners Wealth acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $551,000. Institutional investors own 89.14% of the company's stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares of the company's stock, valued at $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on JAZZ. Needham & Company LLC restated a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Truist Financial boosted their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price on the stock. Finally, The Goldman Sachs Group upped their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research report on Friday, August 29th. Fourteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $178.67.

Jazz Pharmaceuticals Stock Up 2.3%

NASDAQ JAZZ traded up $2.91 during trading hours on Wednesday, reaching $129.45. 96,580 shares of the company's stock were exchanged, compared to its average volume of 928,998. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The company's 50-day moving average is $119.30 and its two-hundred day moving average is $116.30. The company has a market capitalization of $7.85 billion, a price-to-earnings ratio of -19.24, a price-to-earnings-growth ratio of 7.76 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the company earned $5.30 EPS. The company's revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.